GE Healthcare company Clarient Diagnostic Services and molecular diagnostics company Insight Genetics announced a worldwide licensing agreement for intellectual property from Insight Genetics, granting Clarient rights to develop a genetic test covering the anaplastic lymphoma kinase biomarker, a promising target for several classes of cancer drugs. Clarient intends to develop and evaluate the performance characteristics of a quantitative PCR-based test that detects increased transcription of the ALK gene. Several therapeutics compounds, known as ALK inhibitors, are in clinical trials and one, Xalkori, has been approved by the FDA.
A day after she refused to answer questions at a congressional hearing, Lois Lerner has been replaced as director …